Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Loscertales

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Cancers|May 13, 2026
Clinical Implications of Immune Dysfunction in Chronic Lymphocytic LeukemiaLuis Miguel Juárez-Salcedo, Javier Loscertales
Journal of Leukocyte Biology|April 11, 2006
Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemiaManuel Alfonso-Pérez, Sonia López-Giral, Nuria E Quintana, et al.
Mabs|May 4, 2021
Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLLCarlos Cuesta-Mateos, Raquel Juárez-Sánchez, Tamara Mateu-Albero, et al.
Clinical Case Reports|December 28, 2020
Angioimmunoblastic T-cell lymphoma after acute myeloid leukemia: Alleged common pathogenesis. A case report and literature reviewIsabel Iturrate, Javier Loscertales, Elena Fernández-Ruiz, et al.
Cancer Immunology, Immunotherapy : CII|July 23, 2021
Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibodyTamara Mateu-Albero, Raquel Juárez-Sánchez, Javier Loscertales, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 6, 2016
Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in SpainLuis Felipe Casado, Amparo Burgos, Eva González-Haba, et al.
Cancer|November 23, 2006
Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromesPilar Giraldo, Benet Nomdedeu, Javier Loscertales, et al.
Cancers|June 10, 2022
Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migration in T-Cells from Chronic Lymphocytic Leukemia PatientsTamara Mateu-Albero, Ana Marcos-Jimenez, Stefanie Wissmann, et al.
Cancer Immunology, Immunotherapy : CII|March 1, 2015
Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemiaCarlos Cuesta-Mateos, Javier Loscertales, Anna Kreutzman, et al.
Hematological Oncology|August 7, 2023
Evaluation of the novel therapeutic anti-CCR7 antibody CAP-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclaxTamara Mateu-Albero, Ana Marcos-Jimenez, Pablo Delgado-Wicke, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Cancers|May 13, 2026
Clinical Implications of Immune Dysfunction in Chronic Lymphocytic LeukemiaLuis Miguel Juárez-Salcedo, Javier Loscertales
Journal of Leukocyte Biology|April 11, 2006
Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemiaManuel Alfonso-Pérez, Sonia López-Giral, Nuria E Quintana, et al.
Mabs|May 4, 2021
Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLLCarlos Cuesta-Mateos, Raquel Juárez-Sánchez, Tamara Mateu-Albero, et al.
Clinical Case Reports|December 28, 2020
Angioimmunoblastic T-cell lymphoma after acute myeloid leukemia: Alleged common pathogenesis. A case report and literature reviewIsabel Iturrate, Javier Loscertales, Elena Fernández-Ruiz, et al.
Cancer Immunology, Immunotherapy : CII|July 23, 2021
Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibodyTamara Mateu-Albero, Raquel Juárez-Sánchez, Javier Loscertales, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 6, 2016
Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in SpainLuis Felipe Casado, Amparo Burgos, Eva González-Haba, et al.
Cancer|November 23, 2006
Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromesPilar Giraldo, Benet Nomdedeu, Javier Loscertales, et al.
Cancers|June 10, 2022
Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migration in T-Cells from Chronic Lymphocytic Leukemia PatientsTamara Mateu-Albero, Ana Marcos-Jimenez, Stefanie Wissmann, et al.
Cancer Immunology, Immunotherapy : CII|March 1, 2015
Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemiaCarlos Cuesta-Mateos, Javier Loscertales, Anna Kreutzman, et al.
Hematological Oncology|August 7, 2023
Evaluation of the novel therapeutic anti-CCR7 antibody CAP-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclaxTamara Mateu-Albero, Ana Marcos-Jimenez, Pablo Delgado-Wicke, et al.
Pageof 5